Abstract
We analysed clinical and pharmacological factors influencing resistance to clopidogrel in 250 patients with cardiovascular diseases during 18 months. It was shown that the risk ofresistance depends on the form of coronary heart disease, carbohydrate metabolism, the AA genotype of CYP2C19*2 and TBS1 genes. The cardiovascular events significantly morefrequently occurred during 12 and 18 months in resistant diabetics and in the patients with an allele lacking the *2/*3 CYP2C9 gene function and AT/TT polymorphism of the thromboxane synthase gene TBS1.
MeSH terms
-
Alleles
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / metabolism
-
Clopidogrel
-
Cytochrome P-450 CYP2C19 / genetics*
-
Cytochrome P-450 CYP2C19 / metabolism
-
DNA / genetics*
-
Drug Resistance / genetics*
-
Female
-
Genotype
-
Humans
-
Male
-
Middle Aged
-
Platelet Aggregation Inhibitors / therapeutic use
-
Polymorphism, Genetic*
-
Retrospective Studies
-
Thromboxane-A Synthase / genetics*
-
Thromboxane-A Synthase / metabolism
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use
Substances
-
Platelet Aggregation Inhibitors
-
DNA
-
Clopidogrel
-
CYP2C19 protein, human
-
Cytochrome P-450 CYP2C19
-
Thromboxane-A Synthase
-
Ticlopidine